Inventor · disambiguated record
Hagar Kalinski
Also filed as: KALINSKI HAGAR
25 granted patents·21 pending applications·219 citations·filing 2006–2024
96Inventor score
Files withQUARK PHARMACEUTICALS INC15FEINSTEIN ELENA13NITTO DENKO CORP6AVKIN-NACHUM SHARON3KALINSKI HAGAR3
Top patents by PatentIndex Score
46 records- 0195US9932578B2Double-stranded oligonucleotide molecules to P53 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2013·Granted Apr 3, 2018·31 cites·9 claims
- 0295US8741867B2Retinoid-liposomes for treating fibrosisNIITSU YOSHIRO·Filed 2012·Granted Jun 3, 2014·34 cites·29 claims
- 0395US8664376B2Retinoid-liposomes for enhancing modulation of HSP47 expressionNIITSU YOSHIRO·Filed 2012·Granted Mar 4, 2014·30 cites·26 claims
- 0493US10196637B2Retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2016·Granted Feb 5, 2019·7 cites·20 claims
- 0593US9206424B2Modulation of HSP47 expressionNITTO DENKO CORP·Filed 2014·Granted Dec 8, 2015·21 cites·33 claims
- 0692US9121020B2Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·20 cites·23 claims
- 0790US8710209B2Modulation of HSP47 expressionJIN XIAOMEI·Filed 2010·Granted Apr 29, 2014·22 cites·37 claims
- 0889US9456984B2Method for treating fibrosis using siRNA and a retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2014·Granted Oct 4, 2016·10 cites·58 claims
- 0988US8614309B2Double-stranded RNA directed to CASP2 and methods of use thereofFEINSTEIN ELENA·Filed 2008·Granted Dec 24, 2013·11 cites·34 claims
- 1086US10093923B2Modulation of HSP47 expressionNITTO DENKO CORP·Filed 2015·Granted Oct 9, 2018·5 cites·35 claims
- 1186US9446062B2Methods of treating ischemia-reperfusion injury with siRNAsQUARK PHARMACEUTICALS INC·Filed 2015·Granted Sep 20, 2016·4 cites·14 claims
- 1285US10195145B2Method for treating fibrosis using siRNA and a retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2016·Granted Feb 5, 2019·4 cites·31 claims
- 1385US8278287B2siRNA compounds for inhibiting NRF2FEINSTEIN ELENA·Filed 2009·Granted Oct 2, 2012·5 cites·21 claims
- 1481US9701961B2Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2015·Granted Jul 11, 2017·3 cites·20 claims
- 1581US7524935B2Sequences characteristic of hypoxia-regulated gene transcriptionQUARK PHARMACEUTICALS INC·Filed 2006·Granted Apr 28, 2009·1 cites·10 claims
- 1680US8614311B2RTP801L siRNA compounds and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2012·Granted Dec 24, 2013·2 cites·19 claims
- 1775US10421962B2Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2017·Granted Sep 24, 2019·1 cites·6 claims
- 1873US9611474B2Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2013·Granted Apr 4, 2017·1 cites·20 claims
- 1972US9205100B2Compositions and methods for treating lung disease and injuryGELMAN ANDREW E·Filed 2012·Granted Dec 8, 2015·3 cites·6 claims
- 2072US8765931B2Double-stranded oligonucleotide compound for down-regulating the expression of CASP2 geneFEINSTEIN ELENA·Filed 2009·Granted Jul 1, 2014·1 cites·9 claims
- 2171US9822362B2Compositions and methods for treating lung disease and injuryQUARK PHARMACEUTICALS INC·Filed 2015·Granted Nov 21, 2017·1 cites·19 claims
- 2270US9045755B2Double stranded RNA compounds to RhoA and use thereofAVKIN-NACHUM SHARON·Filed 2011·Granted Jun 2, 2015·1 cites·9 claims
- 2368US9487778B2Oligonucleotide modulators of the toll-like receptor pathwayFEINSTEIN ELENA·Filed 2012·Granted Nov 8, 2016·1 cites·16 claims
- 2467US2025114453A1Methods for enhancing therapeutic efficacy of isolated cells for cell therapyLEPTON PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 2563US2024010977A1Methods for enhancing therapeutic efficacy of isolated cells for cell therapyLEPTON PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 2662US2010273854A1Compositions and methods for inhibiting nadph oxidase expressionKALINSKI HAGAR·Filed 2008·Application pending·0 cites
- 2760US2009156524A1Novel siRNAS and methods of use thereofFEINSTEIN ELENA·Filed 2008·Application pending·0 cites
- 2858US2017226519A1METHODS OF TREATING ISCHEMIA-REPERFUSION INJURY WITH siRNASQUARK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2958US2014350068A1Rtp801l sirna compounds and methods of use thereofFEINSTEIN ELENA·Filed 2013·Application pending·0 cites
- 3056US2013267578A1Compositions and methods for inhibiting nadph oxidase expressionKALINSKI HAGAR·Filed 2013·Application pending·0 cites
- 3155US2017306329A1Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3254US2011288155A1Sirna compounds and methods of use thereofFEINSTEIN ELENA·Filed 2009·Application pending·0 cites
- 3353US9796979B2Oligonucleotide modulators of the toll-like receptor pathwayQUARK PHARMACEUTICALS INC·Filed 2016·Granted Oct 24, 2017·0 cites·10 claims
- 3453US2011190380A1Methods for delivery of sirna to bone marrow cells and uses thereofFEINSTEIN ELENA·Filed 2008·Application pending·0 cites
- 3553US2012136044A1Compositions And Methods Of Inhibiting NADPH Oxidase ExpressionKALINSKI HAGAR·Filed 2012·Application pending·0 cites
- 3652US2011028531A1Novel sirna compounds for inhibiting rtp801FEINSTEIN ELENA·Filed 2009·Application pending·0 cites
- 3752US2011105584A1Rtp80il sirna compounds and methods of use thereofFEINSTEIN ELENA·Filed 2008·Application pending·0 cites
- 3852US2011251260A1NOVEL siRNAS AND METHODS OF USE THEREOFQUARK PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 3950US2016333354A1Double stranded rna compounds to rhoa and use thereofAVKIN-NACHUM SHARON·Filed 2016·Application pending·0 cites
- 4049US2013123334A1Novel sirna structuresFEINSTEIN ELENA·Filed 2012·Application pending·0 cites
- 4148US2016102313A1Double stranded rna compounds to rhoa and use thereofAVKIN-NACHUM SHARON·Filed 2015·Application pending·0 cites
- 4247US10781449B2Double-stranded oligonucleotide molecules targeting p53 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2018·Granted Sep 22, 2020·0 cites·11 claims
- 4347US2013030034A9Modulation of timp1 and timp2 expressionQUARK PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 4444US2016281083A1Modulation of timp1 and timp2 expressionNITTO DENKO CORP·Filed 2015·Application pending·0 cites
- 4542US2015018404A1Double-stranded oligonucleotide compounds for treating hearing and balance disordersFEINSTEIN ELENA·Filed 2012·Application pending·0 cites
- 4636US2011034534A1siRNA compounds and methods of use thereofFEINSTEIN ELENA·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →